§ Mr. Simon Hughes
To ask the Secretary of State for Health on which dates the adverse reactions group of the subcommittee on efficacy and adverse reactions and the Committee on Safety of Medicines considered safety issues relating to the antidepressant mianserin; what advice was given to the licensing authority; and on what dates that advice was given. [209311
§ Mr. Malone
Safety issues relating to mianserin were considered by these committees on a number of occasions between 1981 and 1990. The advice given to the Licensing Authority is confidential.